Format

Send to

Choose Destination
Curr HIV/AIDS Rep. 2017 Aug;14(4):123-132. doi: 10.1007/s11904-017-0361-0.

Differentiating HIV-Associated Neurocognitive Disorders From Alzheimer's Disease: an Emerging Issue in Geriatric NeuroHIV.

Author information

1
Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA. Benedetta.Milanini@ucsf.edu.
2
Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.

Abstract

PURPOSE OF REVIEW:

The purpose of this review was to examine characteristics that may distinguish HIV-associated neurocognitive disorder (HAND) from early Alzheimer's disease (AD).

RECENT FINDINGS:

Cerebrospinal fluid (CSF) AD biomarkers are perturbed in HIV, yet these alterations may be limited to settings of advanced dementia or unsuppressed plasma HIV RNA. Neuropsychological testing will require extensive batteries to maximize utility. Structural imaging is limited for early AD detection in the setting of HIV, but proper studies are absent. While positron-emission tomography (PET) amyloid imaging has altered the landscape of differential diagnosis for age-associated neurodegenerative disorders, costs are prohibitive. Risk for delayed AD diagnosis in the aging HIV-infected population is now among the most pressing issues in geriatric neuroHIV. While clinical, imaging, and biomarker characterizations of AD are extensively defined, fewer data define characteristics of HIV-associated neurocognitive disorder in the setting of suppressed plasma HIV RNA. Data needed to inform the phenotype of AD in the setting of HIV are equally few.

KEYWORDS:

Alzheimer’s disease; Biomarkers; Cognitive impairment; HAND; HIV; Neurodegeneration

PMID:
28779301
PMCID:
PMC5823609
DOI:
10.1007/s11904-017-0361-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center